---
title: "First Tracks Biotherapeutics begins Nasdaq trading"
url: "https://aibio.space/news/first-tracks-biotherapeutics-begins-nasdaq-trading-trax-180-million/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2026-04-20"
section: "Mergers"
tickers: "NASDAQ:TRAX"
source: "https://www.sec.gov/Archives/edgar/data/2091349/000119312526164328/d78703dex991.htm"
summary: "The company was spun off from AnaptysBio, Inc. on April 20, 2026. It says it has a two-year cash runway."
---

By the aibio.space news desk.

Sources

- [First Tracks Biotherapeutics, Inc. 8-K (2026-04-20)](https://www.sec.gov/Archives/edgar/data/2091349/000119312526164328/d78703dex991.htm)

[TRAX](https://aibio.space/companies/first-tracks-biotherapeutics/)

2026-04-20

# First Tracks Biotherapeutics begins Nasdaq trading as TRAX with $180 million in cash

Tickers [TRAX](https://aibio.space/companies/first-tracks-biotherapeutics/)

The company was spun off from AnaptysBio, Inc. on April 20, 2026. It says it has a two-year cash runway.

## Key facts

- **Company**: First Tracks Biotherapeutics, Inc. (NASDAQ: TRAX)

- **News type**: Mergers

- **Primary source**: [First Tracks Biotherapeutics, Inc. 8-K (2026-04-20)](https://www.sec.gov/Archives/edgar/data/2091349/000119312526164328/d78703dex991.htm)

*Planning on a whiteboard. Photo: Startup Stock Photos, CC0, via StockSnap. The picture shows the field, not the companies named.*

First Tracks Biotherapeutics, Inc. (Nasdaq: [TRAX](https://aibio.space/companies/first-tracks-biotherapeutics/)) said on April 20, 2026 that it launched as an independent, publicly traded clinical-stage biotechnology company. Its common stock begins trading that day on the Nasdaq Global Select Market under the symbol "TRAX".

The company said it launches with $180 million in cash and a two-year cash runway. The runway is a forward-looking statement, and the company lists its ability to fund development activities among the risks that could change results.

The spin-off was completed after AnaptysBio, Inc. distributed to its shareholders one share of First Tracks common stock for every one share of AnaptysBio common stock owned at the close of business on April 6, 2026, the record date.

First Tracks develops antibody therapies that act on immune pathways tied to autoimmune and inflammatory diseases. Its first three development-stage assets are ANB033, a CD122 antagonist in a Phase 1b trial for celiac disease and eosinophilic esophagitis; rosnilimab, a pathogenic T cell depleter that has completed a Phase 2b trial for rheumatoid arthritis; and ANB101, a BDCA2 modulator in a Phase 1a trial.

Daniel Faga, president and chief executive officer, said ANB033 is the lead operating program.

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

TRAX

First Tracks Biotherapeutics, Inc.

NASDAQ · United States

Open the starter desk

## More in Mergers

Mergers

### [InMed sets November 5 record date for CVRs tied to Mentari merger](https://aibio.space/news/inmed-sets-november-5-record-date-cvrs-tied-mentari-merger/)

Oct 27, 2026

Mergers

### [Rallybio declares estimated $82.7 million cash distribution tied to Avenzo merger](https://aibio.space/news/rallybio-declares-estimated-82-7-million-cash-distribution-tied-avenzo/)

Oct 26, 2026

Mergers

### [Skye Bioscience files preliminary proxy for its Redx Pharma acquisition](https://aibio.space/news/skye-bioscience-files-preliminary-proxy-redx-pharma-acquisition/)

Oct 26, 2026

---
Source page: https://aibio.space/news/first-tracks-biotherapeutics-begins-nasdaq-trading-trax-180-million/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "First Tracks Biotherapeutics begins Nasdaq trading", 2026-04-20, https://aibio.space/news/first-tracks-biotherapeutics-begins-nasdaq-trading-trax-180-million/